A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

NCT05673993 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

381

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Sjogren's Syndrome

Interventions

BIOLOGICAL: Telitacicept 80 mg
BIOLOGICAL: Telitacicept 160 mg
DRUG: Placebo

Sponsor

RemeGen Co., Ltd.